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Abstract Tyrosine kinase inhibitors (TKIs) have rapidly
become an established factor in oncology, and have been
shown to be effective in a wide variety of solid and
hematologic malignancies. Use of the oral administration
route of TKIs offers flexibility and is convenient for the
patient; however, despite these advantages, the oral route
of administration also causes a highly relevant new prob-
lem. Acid-inhibitory drugs, such as proton pump inhibitors
(PPIs), increase the intragastric pH, which may subse-
quently decrease TKI solubility, bioavailability, and treat-
ment efficacy. Clear and practical advice on how to
manage PPI use during TKI therapy is currently not
available in the literature. Since PPIs are extensively used
during TKI therapy, prescribers are presented with a big
dilemma as to whether or not to continue the combined
treatment, resulting in patients possibly being deprived of
optimal therapy. When all pharmacological characteristics
and data of either TKIs and PPIs are considered, practical
and safe advice on how to manage this drug combination
can be given.
Key Points
TKIs have become an established factor in oncology
but concomitant use of PPIs decrease TKI
bioavailability.
Since PPI use is associated with decreased TKI
efficacy, prescribers are posed with a great dilemma
whether or not to continue the combined treatment.
When all pharmacological characteristics are
considered, a practical and safe advice on how to
manage this drug combination can be given.
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1 Introduction
Tyrosine kinase inhibitors (TKIs) have rapidly become an
established factor in daily oncology practice [1], and have
been shown to be effective in a wide variety of solid and
hematologic malignancies. At present, there are 25 EMA-
approved TKIs, and many new TKIs are under investigation
[2]. Use of the oral administration route of TKIs offers
logistic flexibility and is convenient for the patient [3];
however, despite these advantages, the oral route of
administration also causes a highly relevant new problem.
For TKIs in particular, the poor and variable bioavailability,
together with other variable pharmacokinetic factors, con-
tribute to a significant in- and between-patient variability in
plasma levels and exposure [4]. Most importantly, acid-in-
hibitory drugs, such as proton pump inhibitors (PPIs),
increase the intragastric pH, which may decrease the solu-
bility and thereby the biological availability of certain TKIs.
Although there are no prospective studies available, some
retrospective data clearly showed that PPI use was associ-
ated with decreased TKI efficacy [5–7].
Although PPIs are extensively used during anticancer
treatment, there is still much controversy on how to manage
drug–drug interactions (DDIs) between TKIs and PPIs [8, 9].
To address this, guidelines are provided by the FDA and the
European Medicines Agency (EMA) that recommend
studying the DDI between pH-dependent drugs and PPIs.
Accordingly, for some TKIs the effect of a PPI on absorption
from the gut is thoroughly investigated, and specific guide-
lines for the management of such DDIs are provided in the
product label [2]. However, for other TKIs (e.g. afatinib,
regorafenib, sunitinib, trametinib and vemurafenib), only
basic preclinical pharmacokinetic studies have been exe-
cuted to date and the in vivo effect of PPIs on these com-
pounds remains unknown.
Next to other factors, TKI therapy is associated with a
higher risk for gastrointestinal disorders. Therefore, for
many cancer patients using TKIs, there is a solid indication
for gastroprotection or treatment of gastrointestinal symp-
toms with PPIs [8, 10]. Although not all TKIs show a
significant DDI with PPIs, indecisive guidelines still pre-
sent prescribers with a dilemma as to whether or not to
continue the combined treatment in individual patients [1].
2 Unraveling Drug–Drug Interactions
between Tyrosine Kinase Inhibitors (TKIs)
and Proton Pump Inhibitors (PPIs)
To appreciate the background of the DDI between TKIs
and PPIs, we review theoretical pharmacokinetic and
pharmacodynamic principles, as well as known pharma-
cokinetic DDI studies.
2.1 TKI Absorption and Intragastric pH
Although the absorption of TKIs may be influenced by
many factors, the major determinant in TKI absorption is
the pH-dependent solubility [1, 11]. Since TKIs are weakly
basic, there is an equilibrium between the ionized and non-
ionized form that is dependent on intragastric pH. At
normal acidic intragastric pH (pH range 1–2), the equi-
librium shifts to the ionized form. Since the ionized form
has better solubility, TKI absorption from the gastroin-
testinal tract is optimal at low intragastric pH; however,
when the intragastric pH is elevated (e.g. due to concurrent
PPI use), the balance shifts towards the non-ionized form
of the drug and solubility and bioavailability may decrease
significantly [1, 12].
2.2 PPI Pharmacology
Besides TKI bioavailability, the pharmacological profile of
PPIs is important to consider for the management of DDIs
between TKIs and PPIs. PPIs are highly effective acid-
inhibitory agents and are registered in a once-daily dose for
the majority of their indications. Although this dosing
strategy is usually effective in controlling gastroesophageal
reflux disease, PPIs do not elevate the intragastric pH over
the full 24-h range (see Fig. 1) [13–16]. There are two
important explanations for this 24-h variation in acid sup-
pression: (1) the delayed onset of the pharmacological
effect of PPIs; and (2) the duration of pharmacological
action [16, 17].
For most PPIs, the acid-inhibitory effects (defined by an
intragastric pH[4) will only be reached 3–4 h after intake
[16–19]. This delayed onset of action is caused predomi-
nantly by the use of enteric-coated tablets or capsules.
Since PPIs are easily protonated, they are unstable at low
(intragastric) pH and therefore a coating is indicated.
Polymer coatings are stable at low intragastric pH, but
break down easily at higher intestinal pH. As a result, the
PPI is protected against degradation in the stomach and
arrives intact in the duodenum where absorption takes
place. Furthermore, the mechanism of action of PPIs
through inhibiting the hydrogen/potassium adenosine
triphosphatase enzyme (H?/K? ATPase) in gastric cells
may also cause a further delay of action [20]. The resulting
delay of acid-inhibitory effects after administration
amounts to an average of 3–4 h (Fig. 1).
Although most PPIs are characterized by a short half-life
(t) of approximately 1–2 h, the pharmacodynamic effects
on intragastric pH last much longer because of its irre-
versible covalent binding to the proton pumps. After
2–3 days of daily use, a steady state in acid inhibition is
reached [13, 20]. Meanwhile, new proton pumps are gen-
erated in vivo on a continuous basis, and, subsequently,
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gastric acid will be secreted from these new pumps, com-
pensating the elevated pH [16]. As a consequence, the
intragastric pH will start to decrease again and drops to pH
values\4 within 12–14 h after PPI administration (Fig. 1)
[16]. On the other hand, during nighttime, physiological
duodenogastric reflux occurs as a result of the supine
position during sleep. As a result, there is an elevation in
intragastric pH during nighttime which sharply returns to
baseline after getting out of bed (Fig. 1) [16]. Furthermore,
a substantial proportion of patients above 80 years of age
experience achlorhydria, a state in which the production of
hydrochloric acid in the stomach is low or absent and the
intragastric pH is substantially elevated [21]. Both night-
time duodenogastric reflux and achlorhydria in older
patients may profoundly alter TKI bioavailability. More-
over, TKI bioavailability can be profoundly influenced
when taken with food (e.g. lapatinib) [22]. Food may sig-
nificantly enhance TKI bioavailability by elevating intra-
gastric pH and drug absorption, resulting in high intra- and
interpatient variability. For this reason, patients are often
advised to take a TKI in a fasting state. Of note, in serious
gastroesophageal reflux disease, physicians may prescribe
a PPI in a twice-daily dose. In contrast to a once-daily dose,
more frequent dosing of PPIs (e.g. twice-daily or contin-
uous dosing) leads to a greater and more constant elevation
of intragastric pH over the full 24-h range [10].
2.3 Available Drug–Drug Interaction Studies
and Study Design
As mentioned in Sect. 2.2, the intragastric pH is not ele-
vated over the full 24-h range during PPI therapy. There-
fore, the outcomes of DDI studies between a PPI and a TKI
are highly dependent on the study design, especially the
time of intake for both the TKI and the PPI. Two types of
studies can be distinguished: (1) the TKI and PPI are
administered concomitantly; and (2) the TKI is adminis-
tered 2–3 h after the intake of the PPI. There are strengths
and limitations for both types of study designs.
When the drugs are taken concomitantly, and if the
observed effect is low/nihil, this may indicate that there is
indeed no interaction between the two drugs, but it may
also well be that a DDI would have been observed if the
PPI had been taken at another time [2, 23]. As mentioned
previously, when the TKI and PPI are administered con-
comitantly, there is a time window of low intragastric pH
Administration
of TKI and PPI
Nocturnal
duodenogastric
reflux peak
Delayed
onset
PPI
Duration of pharmacological action PPI
7
6
5
4
3
2
1
pH-dependent solubility:
Afetinib*, Axitinib, Cabozantinib, Crizotinib,
Imatinib, Nilotinib, Nintedanib*, Ponatinib, 
Regorafenib, Ruxolitinib*, Sorafenib, 
Sunitinib*, Trametinib*, Vandetanib, 
Vemurafenib*
pH-dependent solubility:
Bosutinib, Cabozantinib, Dabrefenib*, 
Dasatinib, Erlotinib, Gefitinib, Ibrutinib*, 
Lapatinib, Pazopanib
pH
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Ti me after intake PPI (h)
Fig. 1 Schematic 24-h intragastric pH curve during PPI use (enteric-
coated, once daily) with delayed onset of action (3–4 h), duration of
action (12–14 h with once-daily use) and the nocturnal duodenogas-
tric reflux peak (obtained by the supine position during sleep).
Derived from Hunfeld et al. [16], with permission. *Based on in vitro
preclinical studies only. TKI tyrosine kinase inhibitor, PPI proton
pump inhibitor
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after PPI intake in which the TKI absorption will not be
significantly affected, which may potentially lead to a false
perception that, regardless of the time of intake of either
the PPI and TKI, no DDI occurs. For some TKIs (e.g.
axitinib and nilotinib [2]), the question remains whether an
alternative time schedule of PPI to TKI intake would lead
to an increase or decrease in the TKI absorption, as this is
unfortunately rarely studied. Therefore, if no clinically
relevant effect is seen in studies while these drugs are taken
at the same time, the subsequently drawn conclusion that
‘TKIs and PPIs may be used concomitantly’ should, in our
opinion, be replaced by ‘TKIs and PPIs must be used
concomitantly’, to guarantee safe use.
When a TKI is administered a few hours after a PPI, the
intragastric pH is almost certainly elevated. When no pH-
dependent solubility is expected, a study setup where the
TKI is administered a few hours after the PPI might be best
in order to completely rule out an absorption-based DDI, as
was shown for cabozantinib [24].
2.4 Management of TKI–PPI Drug Interactions
There is often a hard indication for concomitant use of
TKIs and PPIs; however, in clinical practice, clinicians are
often advised to avoid the combination [13], often resulting
in the patient being deprived of optimal therapy for gas-
troesophageal reflux disease.
For several TKIs approved by the FDA, the effect on
bioavailability has only been studied in vitro, whereas pH-
dependent solubility and TKI absorption in vivo is often
multifactorial [4]. In this case, only preclinical in vitro data
on chemical pH-dependent solubility may not predict the
true in vivo effects on bioavailability (e.g. afatinib, rego-
rafenib, sunitinib, trametinib and vemurafenib [2]) of
concomitantly used PPIs. If it is stated that there is no
significant DDI between a certain TKI and PPI, this should
be confirmed in an adequately designed in vivo pharma-
cokinetic DDI study, or should be based on population
pharmacokinetics for DDI assessment using data from
large clinical trials.
A lot of discussion has taken place as to whether TKIs
and PPIs are really incompatible. There is the interesting
suggestion by Ter Heine et al. that when the PPI dose (in
this case pantoprazole) is relatively low, erlotinib can be
used concomitantly. However, this recommendation is
based on a single case study, and solid pharmacokinetic
data provided in the FDA assessment report stated other-
wise (mentioning a 46 and 61% decrease in erlotinib area
under the concentration–time curve [AUC] and maximum
concentration [Cmax], respectively) [2, 25]. Although many
pharmacokinetic DDI studies have already been conducted
and have been published in either an EMA/FDA assess-
ment report or scientific literature, clear advice on the
management of the DDI between PPIs and TKIs is rarely
given. Studies on alternative time schedules of PPI to TKI
intake to completely rule out a DDI are also scarcely
available, and drawn conclusions on the management (e.g.
can be used concomitantly) may not always be 100% solid.
Clearly, the investigated effect of a PPI on a certain TKI
should always be placed in the context of clinical rele-
vance. For instance, if the effect of a PPI on TKI
bioavailability does not influence drug efficacy (e.g. B20%
decrease), this DDI should be considered as non-
significant.
Due to the nocturnal duodenogastric reflux peak, intra-
gastric pH is elevated during sleep [16, 26]. Because of
this, the advice to take a TKI without food in the evening
concomitantly with a PPI, as was stated in the label of
pazopanib, may significantly influence TKI bioavailability
[2]. On theoretical grounds (and regardless of PPI use), the
bioavailability of TKIs may not be optimal when taken ante
noctem and should be avoided accordingly. Furthermore,
patients receiving TKI therapy, especially those 80 years of
age and older, might experience achlorhydria with a sub-
optimal absorption as a result [21]. More research is needed
to investigate TKI bioavailability during nighttime sleep,
and achlorhydria. Although it may significantly enhance
TKI bioavailability, patients are often advised to take a
TKI without food. As a result, the management of the DDI
between the PPI and TKI with regard to food intake (2 h
before and 1 h after TKI intake), in clinical practice, also
appears to be challenging. When using pantoprazole
instead of other PPIs, TKI pharmacokinetics may be altered
through inhibition of drug transporters such as Breast
Cancer Resistance Protein (BCRP) and P-glycoprotein (P-
gp) [27]. Since many TKIs are substrates for BCRP and/or
P-gp, physicians should prescribe pantoprazole with cau-
tion, or switch to other PPIs, such as omeprazole, during
TKI therapy. Moreover, for these TKIs, results obtained
from drug interaction studies with omeprazole may not be
extrapolated directly to pantoprazole. More research is
needed to explore the clinical significance of the DDI
between pantoprazole and TKIs.
Several studies have shown that there is large interpa-
tient variability in the onset of action of PPIs. Moreover,
there is also large variability in the onset of action between
different PPIs and between brand and generic formulas
(inter-PPI variability) [16, 17, 28, 29]. Due to these factors,
in theory, the delayed onset of action may be significantly
shorter. To completely rule out any interpatient and inter-
PPI variability, and to give suitable advice for the man-
agement of the DDI between TKIs and all PPIs, TKIs
should be taken 2 h before the PPI. Furthermore, PPIs can
be administered either as an enteric-coated (e.g. Losec or
Nexium) or instant-release formula (e.g. Zegerid). Since
the abovementioned delayed onset of action and
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subsequent window of low intragastric pH is used to
manage the DDI between TKIs and PPIs, only the enteric-
coated formula should be used.
We recently showed that the intake of erlotinib with an
acidic beverage (cola) enhanced bioavailability by almost
40% in patients also taking esomeprazole [30]. Through
temporarily lowering the intragastric pH by administering
the TKI with cola, the DDI between TKIs and PPIs can be
bypassed (partly). In particular, when there is a hard indi-
cation for twice-daily use of a PPI, in our opinion cola may
be a simple and practical solution to manage the DDI
between TKIs and PPIs.
When all pharmacological characteristics and data of
either TKIs and PPIs are considered, balanced, practical
and safe advice on how to manage this drug combination
can be given. Since the intragastric pH is not elevated over
the whole 24-h range (as shown in Fig. 1), a target period
of low intragastric pH can be used to safely administer the
TKI.
3 Conclusions
Clinicians and pharmacists should always first assess
whether or not there is a clinically relevant DDI between a
certain TKI and PPIs. To properly manage a significant
DDI between TKIs and PPIs, a twice-daily PPI dose must
first be brought back to a once-daily regimen, whereas the
PPI must be administered in an enteric-coated formulation.
If the TKI is administered in the morning, 2 h prior to
intake of the PPI, the enteric coating of the PPI will provide
a target period of low intragastric pH during which TKIs
with a pH-dependent solubility can pass through the
stomach with sufficiently low pH. More research on
alternative timing schedules of PPI to TKI intake,
achlorhydria, and nighttime TKI absorption is necessary as
this will provide further insights into the effects of elevated
intragastric pH on TKI bioavailability.
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